期刊文献+

前列腺特异性抗原位于灰区患者前列腺癌危险因素及预测模型

Risk factors and predictive models for prostate cancer in patients with gray zone prostate-specific antigen levels
暂未订购
导出
摘要 目的基于血尿生化指标和临床参数探寻血清前列腺特异性抗原(prostate specific antigen,PSA)位于灰区时(4~10ng/m1)前列腺癌的危险因素,筛选具有临床价值的指标,并根据相关指标构建前列腺癌的预测模型。方法选取2023年3月至2025年3月南京中医药大学附属医院(江苏省中医院)泌尿外科收治的238例血清PSA为4~10ng/ml且接受经会阴前列腺穿刺活检的患者作为研究对象,根据病理结果分为良性前列腺增生组(n=135)和前列腺癌组(n=103)。分析患者年龄、体质量指数(body mass index,BMI)、总前列腺特异性抗原(total prostate specific antigen,tPSA)、游离前列腺特异性抗原(free prostatespecific antigen,fPSA)、fPSA/tPSA、前列腺体积(prostate volume,PV)、前列腺特异性抗原密度(prostate specific antigen density,PSAD)、血尿常规、血生化、高血压、糖尿病、脑梗死、高血脂症、前列腺影像报告和数据系统2.1版(prostate imaging reporting and datasystem version2.1,PI-RADSv2.1)等指标,使用二元logistic回归分析评估对前列腺癌有预测价值的指标,进而建立诊断前列腺癌的预测模型Logit(P)并绘制ROC曲线,比较各独立变量和预测模型Logit(P)的曲线下面积,选取各因素和预测模型Logit(P)的最佳截断值,以此评估其诊断效能。结果两组患者年龄、fPSA、fPSA/tPSA、PV、PSAD、脑梗死病史、PI-RADSV2.1等因素比较,差异均有统计学意义(P<O.05),其中,年龄、fPSA/tPSA、PV、PSAD、PI-RADSv2.1是预测前列腺癌的相关因素,其用于诊断前列腺癌的曲线下面积分别为0.586、0.343、0.217、0.735、0.714。基于临床因素构建预测模型为:Logit(P)=年龄×0.074-PV×0.02+PI-RADSV2.1×O.643-fPSA/tPSA×0.062-4.531,预测模型Logit(P)的ROC曲线下面积为O.831。结论基于年龄、fPSA/tPSA、PI-RADSV2.1以及PV建立的联合预测模型的诊断效能高于单一指标,在有限的检查项目中可有效降低前列腺癌的漏诊率,减少不必要的前列腺穿刺。 Objective To identify the risk factors of prostate cancer when serum prostate-specific antigen(PSA)is in the gray zone(4-10 ng/ml)based on hematuria biochemical indicators and clinical parameters,screen out indicators with clinical value,and construct a prostate cancer prediction model using the relevant indicators.Methods The clinical data of 238 patients with serum PSA levels ranging from 4 to 10ng/ml who underwent transperineal prostate biopsy in the Department of Urology,Jiangsu Provincial Hospital of Traditional Chinese Medicine from March 2023 to March 2025 were collected.According to the pathological results,the patients were divided into the benign prostatic hyperplasia group(135 cases)and the prostate cancer group(103 cases).Indicators including age,BMI,total PSA(tPSA),free PSA(fPSA),fPSA/tPSA ratio,prostate volume(PV),PSA density(PSAD),blood routine,urine routine,blood biochemistry,hypertension,diabetes,cerebral infarction,hyperlipidemia,and PI-RADS score were analyzed.Binary logistic regression analysis was employed to evaluate the indicators with predictive value for prostate cancer.Subsequently,a prediction model Logit(P)for the diagnosis of prostate cancer was established,and receiver operating characteristic(ROC)curves of each independent variable and the prediction model Logit(P)were plotted.The area under the curve(AUC)of each independent variable and the prediction model was compared,and the optimal cut-off values of each factor and the prediction model were selected to assess their diagnostic efficacy.Results There were statistically significant differences in age,fPSA,fPSA/tPSA ratio,PV,PSAD,history of cerebral infarction,and PI-RADS score between the two groups(P<O.05).Age,fPSA/tPSA ratio,PV,PSAD,and PI-RADS score were identified as independent predictive indicators for prostate cancer.Their AUCs for the diagnosis of prostate cancer were 0.586,0.343,0.217,0.735,and 0.714,respectively.The prediction model constructed based on clinical factors was Logit(P)=0.074×age-0.02×PV+0.643×PI-RADS score-0.062×fPSA/tPSA−4.531.The AUC of the Logit(P)model was 0.831.Conclusion The diagnostic efficacy of the combined prediction model based on age,fPSA/tPSA ratio,PI-RADS score,and PV is higher than that of any single indicator.When examination items are limited,this model can effectively reduce the missed diagnosis rate of prostate cancer and decrease unnecessary prostate punctures.
作者 徐渭 张犁 Xu Wei;Zhang Li(Department of Urology,Affiliated Hospital of Nanjing University of Chinese Medicine,Nanjing,Jiangsu 210000,China)
出处 《泌尿外科杂志(电子版)》 2025年第4期31-37,共7页 Journal of Urology for Clinicians(Electronic Version)
关键词 前列腺癌 前列腺特异性抗原 临床因素分析 Prostate cancer Prostate-specific antigen Analysis of clinical factors
  • 相关文献

参考文献9

二级参考文献63

  • 1孙浩瑜,姜鑫,陈守臻,曲思凤,史本康.多参数磁共振联合前列腺健康指数对PSA灰区临床有意义前列腺癌的诊断价值[J].山东大学学报(医学版),2022,60(6):46-50. 被引量:13
  • 2Timothy J W,MacDonald R,Rutks I,et al.Systematic Review:comparative effectiveness and harms of treatments for clinically localized prostate cancer.Ann Intern Med,2008,148:435-448.
  • 3Greg LS,Wilson P,Cuzick J,et al.International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate:a meta-analysis of 1446 patients.BJU Int,2007,99:1056-1065.
  • 4De Conti P,Atallah (A)N,Arruda HO,et al.Intermittent versus continuous androgen suppression forprostatic cancer.http;//www.thecochranelibrary.com.
  • 5Moon C,Park JC,Chae YK.Current status of experimental therapeutics for prostate cancer.Cancer Letters,2008,266:116-134.
  • 6Jemal A,Siegel R,Ward E,et al.Cancer statistics.CA Cancer J Clin,2007,57:43-66.
  • 7Dall'Era MA,Cooperberg MR,Chan JM,et al.Active surveillance for early-stage prostate cancer:review of the current literature.Cancer,2008,112:1650-1659.
  • 8Andriole CL,Grubb RL,Buys SS,et al.Mortality results from a randomized prostatecancer screening trial.N Engl J Med,2009,360:1310-1319.
  • 9Yin M,Bastacky S,Chandran,U,et al.Prevalence of incidental prostate cancer in thegeneral population:a study of healthy organ donors.J Urol,2008,179:892.
  • 10Rafael FC,Chauhan S,Kenneth JP,et al.Robotic-assisted radical prostatectomy:a review of current outcomes.BJU Int,2009,104:1428-1435.

共引文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部